Kitov Pharmaceuticals Holdings Ltd. announced that the Board determined to fill a vacancy on the Board, and to appoint, effective immediately, Ms. Leah Bruck to serve as a director of the company. Since 2012, Ms. Bruck has been the principal owner of a business which provides CFO, controllership and accounting services to Israeli companies, including a number of publicly traded corporations. As part of these engagements, from April 2012 until June 2016, Ms. Bruck's business provided controllership and bookkeeping services to the company, and to Mainrom Line Logistics Ltd., a TASE listed company into which Kitov Pharmaceuticals Ltd. merged in July 2013. The Board carried out the first division of the Board of Directors into three classes, as set in Article 84 of the Company's Amended and Restated Articles of Association. In accordance with such resolution, each of Drs. Paul Waymack and Alain Zeitoun were appointed to the first class of directors, with Dr. Waymack to serve until the 2016 Annual General Meeting, and Dr. Zeitoun to serve until December 16, 2016, the completion of his original term as a director, in accordance with the transition rules for directors previously classified as external directors, as set under Regulation 5D of the Israeli Companies Regulations, 5760-2000, which were adopted by the company on July 13, 2016. Messrs. Steven Steinberg, Ido Agmon and Yair Katzir were each appointed to the second class of directors to serve until the 2017 Annual General Meeting, and Messrs. Isaac Israel and Simcha Rock and Ms. Leah Bruck, were appointed to the third class of directors to serve until the 2018 Annual General Meeting.